sponsored
PatientsVille.com Logo

PatientsVille

Namenda Medical Research Studies

Up-to-date List of Namenda Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Namenda Medical Research Studies

Rank Status Study
1 Recruiting Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?
Condition: Epilepsy
Interventions: Drug: Memantine;   Other: Sugar Pill
Outcome Measures: The change scores from pre- and post-treatment neuropsychological test evaluations will be compared between the placebo and memantine treatment groups. If the distributions are normal, we will perform a two-sample t-test.;   To test the hypothesis that improvement will be selective for verbal memory, change scores on the non-verbal tasks will be compared between the placebo and memantine treatment groups. If the distributions are normal, we will conduct a two-sample t-test.;   To test the hypothesis that treatment with memantine will result in subjective improvement of memory function, the change scores from the QOLIE-89 will be evaluated. If the distributions are normal, we will proceed with a two-sample t-test;   A secondary analysis will examine the possible sustained benefit of continued memantine use.
2 Unknown  The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?
Condition: Major Depressive Disorder
Interventions: Drug: memantine;   Drug: Placebo
Outcome Measures: Assessment of whether Memantine protects memory and cognitive impairment caused by ECT.;   Whether memantine will improve response of Depression to Electroconvulsive therapy.
3 Unknown  Donepezil and Memantine in Moderate to Severe Alzheimer's Disease
Condition: Moderate to Severe Alzheimer's Disease
Interventions: Drug: Memantine;   Drug: Donepezil;   Drug: Placebo donepezil;   Drug: Placebo memantine
Outcome Measures: Cognitive Function measured with the Standardised MMSE (SMMSE).;   Activities of Daily Living measured with the Bristol Activities of Daily Living scale (BADLS).;   Non−cognitive dementia symptoms measured with the Neuropsychiatric Inventory (NPI) and the Cohen−Mansfield Agitation Inventory.;   Health−related quality of life measured with the EQ−5D (Euroqol Group 1990) and the DEMQOL−Proxy (Smith et al 2004) − a carer−rated and disease−specific measure of quality of life in dementia.;   Care−giver burden measured with the General Health Questionnaire.;   Cost effectiveness assessed through consideration of the combination of costs generated from the Client Service Receipt Inventory (CSRI) and the assessments of function and quality of life (BADLS, DEMQOL, EQ−5D).;   Institutionalisation defined as permanent transition from living in an independent household to a care home, NHS continuing care unit or hospital and measured with questions taken from the CSRI and telephone interviews.
4 Recruiting Prophylaxis of Neuropathic Pain by mémantine
Condition: Neuropathic Pain
Interventions: Drug: Memantine EBIXA®;   Drug: Placebo : lactose
Outcome Measures: average painful intensity;   Evaluation of pain by numerical scale;   Average painful;   analgesic consumption
5 Not yet recruiting Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Memantine;   Drug: Placebo
Outcome Measures: Change from baseline in neurocognitive function;   Change from baseline in symptom severity during 12 weeks;   Change from baseline in adverse events during 12 weeks
6 Not yet recruiting Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorders
Condition: Autism Spectrum Disorder
Intervention: Drug: Memantine
Outcome Measure: Aberrant Behavior Checklist-Social Withdrawal Subscale
7 Recruiting Memantine for Enhanced Stroke Recovery
Conditions: Ischemic Stroke;   Upper Extremity Weakness
Interventions: Drug: Memantine;   Drug: Placebo (for memantine)
Outcome Measures: Fugl-Meyer Assessment;   Adverse events;   Adverse Events;   Motor Activity Log (MAL);   Ten Meter Walk Test;   Stroke Impact Scale (SIS);   Cancellation Tests;   Cancellations Tests;   Grip Strength Test;   Montreal Cognitive Assessment (MoCA©)
8 Recruiting Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)
Condition: Brain Cancer
Interventions: Drug: Temozolomide;   Drug: Memantine;   Drug: Mefloquine;   Drug: Metformin
Outcome Measures: Maximum Tolerated Dose (MTD) Levels;   Progression Free Survival (PFS)
9 Not yet recruiting Randomised Controlled Trial of Memantine in Fibromyalgia
Condition: Fibromyalgia
Interventions: Drug: Memantine;   Drug: Placebo
Outcome Measures: Change from baseline in pain threshold at month 1;   Change from baseline in pain threshold at month 3;   Change from baseline in pain threshold at month 6;   Change from baseline in pain perception at month 1;   Change from baseline in pain perception at month 3;   Change from baseline in pain perception at month 6;   To assess improvement in cognitive state;   To assess improvement in Health Status;   To assess Anxiety and depression levels;   To assess Quality of life;   To assess Clinical Global Impression;   Glutamate levels in different brain regions (insula, hippocampus and posterior cingulate cortex).
10 Recruiting Therapy in Amyotrophic Lateral Sclerosis With Memantine at 20 mg BID (TAME)
Conditions: Amyotrophic Lateral Sclerosis;   Frontal Temporal Dementia
Interventions: Drug: Memantine;   Drug: Placebo (for Memantine)
Outcome Measures: Disease progression as measured by the number of points lost on the ALS Functional Rating-Scale-Revised (ALSFRS-R);   Measuring the levels of Tau, pNFH and the pNFH/C3 ratio in CSF and blood
11 Recruiting Brain Aging and Treatment Response in Geriatric Depression
Conditions: Mild Neurocognitive Disorder;   MCI;   Depression
Interventions: Drug: Escitalopram;   Drug: Memantine;   Drug: Placebo
Outcome Measures: Change in Hamilton Depression Rating Scale (HDRS) scores;   Change in cognitive domain scores
12 Recruiting Naltrexone and Memantine Effects on Alcohol Drinking Behaviors
Condition: Alcohol Drinking
Interventions: Drug: Naltrexone and memantine;   Drug: Naltrexone and Placebo
Outcome Measures: number of drinks consumed;   Stimulation and sedation responses to alcohol
13 Recruiting Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder
Condition: Obsessive-Compulsive Disorder
Intervention: Drug: Memantine
Outcome Measures: Yale-Brown Obsessive Compusive Scale (YBOCS);   Hamilton Depression Rating Scale (HAM-D)
14 Recruiting A Trial of Memantine Versus Placebo in Children With Autism
Condition: Autism Spectrum Disorder
Intervention: Drug: Memantine
Outcome Measures: NEPSY apraxia and repetition of nonsense words subtests;   Vineland Adaptive Behavior Scale - Revised;   Safety Monitoring Uniform Research Form
15 Recruiting Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease
Conditions: Alzheimer's Disease;   Dementia
Interventions: Drug: Ebixa;   Drug: donepezil
Outcome Measures: AQ-WAB(Western aphasia battery);   ROSA (Relevant Outcome Scale for Alzheimer's Disease)
16 Recruiting Memantine on Aggression and Agitation of Alzheimer's Disease (AD)
Condition: Alzheimer's Disease
Intervention: Drug: Memantine
Outcome Measures: CMAI score;   CBI score;   RUD;   NPI score
17 Unknown  Alzheimer's Disease - Input of Vitamin D With mEmantine Assay
Condition: Alzheimer Disease
Interventions: Drug: Memantine;   Drug: Vitamin D;   Drug: Vitamin D placebo
Outcome Measures: Change in cognitive performance;   Change in other cognitive scores;   Change in functional performance;   Change in posture and gait;   Between-group comparison of compliance to treatment and tolerance
18 Unknown  Memantine for Post-Operative Pain Control
Condition: Pain, Post-operative
Interventions: Drug: Memantine;   Drug: Placebo
Outcome Measures: Change in numerical ratings on pain diaries as outpatients (pre and post surgery);   Daily pain numerical ratings at rest and with movement as inpatients.;   Total opiate dose via patient controlled IV hydromorphone;   Oxycodone dose taken prn;   Treatment group differences in side effects (nausea, itching, sedation, urinary retention following foley catheter discontinuation);   Changes in cognitive function, assessed with Digit-Symbol Substitution Test and Trail Making Test B;   Changes in pain and quality of life questionnaire responses (SF-McGill-2, Brief Pain Questionnaire, SF-36 v2)
19 Recruiting A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults
Conditions: Healthy Volunteers;;   Obese, Otherwise Healthy Volunteers
Interventions: Drug: Baclofen;   Drug: Memantine;   Drug: Placebo
Outcome Measures: Safety and tolerability of co-administered baclofen and memantine via C-SSRS;   Safety and tolerability of co-administered baclofen and memantine via Adverse Events;   Safety and tolerability of co-administered baclofen and memantine via Vital Signs;   Safety and tolerability of co-administered baclofen and memantine via ECG;   Safety and tolerability of co-administered baclofen and memantine via Clinical Laboratory Tests;   Pharmacokinetic parameters of co-administered baclofen and memantine via Cmax;   Pharmacokinetic parameters of co-administered baclofen and memantine via Tmax;   Pharmacokinetic parameters of co-administered baclofen and memantine via AUC;   Pharmacokinetic parameters of co-administered baclofen and memantine via MRT;   Pharmacokinetic parameters of co-administered baclofen and memantine via CL/F;   Pharmacokinetic parameters of co-administered baclofen and memantine via T1/2;   Pharmacokinetic parameters of co-administered baclofen and memantine via CLR
20 Unknown  Study of Memantine to Treat Huntington's Disease
Condition: Huntington's Disease
Intervention: Drug: Memantine
Outcome Measures: sensitive neuropsychological battery;   behavioral and functional measures at three and six months of treatment

These studies may lead to new treatments and are adding insight into Namenda etiology and treatment.

A major focus of Namenda research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Namenda